Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.710 +0.360 (+5.67%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Precision Medicine Could Get Even More Precise With Allarity Therapeutics' "Next-Generation" Diagnostics Platform ↗
Allarity Therapeutics Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on oncology treatments. 
Via Benzinga
News headline image
Analyst Initiates Coverage On This Genetic Testing Stock With Ongoing Transformation ↗
 
Via Benzinga
News headline image
Is Illumina Still the Gamechanger in Genomics Sequencing?
Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused 
Via MarketBeat
Topics Earnings Economy Lawsuit
News headline image
Recap: Myriad Genetics Q1 Earnings ↗
Myriad Genetics (NASDAQ:MYGN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:05 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Earnings Scheduled For November 2, 2021 ↗
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
What's Up With Myriad Genetics Shares Trading Higher Tuesday? ↗
Myriad Genetics, Inc. (NASDAQ:MYGN) shares are trading hig... 
Via Benzinga
News headline image
Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Can Artificial Intelligence Predict Our Future Health? ↗
Thousands of financial investors and Wall Street pundits advise people daily about what economic trends are coming, what stocks are hot and what is on the upswing. Those same investors and banks... 
Via Benzinga
News headline image
40 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares jumped 360.8% to $9.86 after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Myriad Genetics's Earnings: A Preview ↗
Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Myriad... 
Via Benzinga
News headline image
77 Biggest Movers From Yesterday ↗
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate... 
Via Benzinga
News headline image
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis ↗
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was... 
Via Benzinga
News headline image
AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer ↗
The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) cancer drug, jointly developed with Merck & Co Inc (NYSE: MRK) to treat patients with early-... 
Via Benzinga
News headline image
Myriad Genetics, Inc (MYGN) Q3 2021 Earnings Call Transcript ↗
MYGN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
Myriad Genetics Insider Sold Over $None In Company Stock ↗
Nicole Lambert, Corporate Officer at Myriad Genetics (NASDAQ:MYGN), made a large insider sell on September 27, according to a new SEC filing. What Happened: A Form 4 filing from... 
Via Benzinga
Topics Regulatory Compliance
News headline image
4 Stocks Insiders Are Buying ↗
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go... 
Via Benzinga
News headline image
75 Biggest Movers From Yesterday ↗
Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares climbed 68.1% to close at $58.25 on Tuesday after the company announced that the it has received approval for a... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
News headline image
Myriad Genetics, inc (MYGN) Q2 2021 Earnings Call Transcript ↗
MYGN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
48 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 64.4% to $7.15 after a Form 4 filing from the company showed 10% shareholder Retail Ecommerce Ventures... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
News headline image
Earnings Scheduled For August 3, 2021 ↗
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.